How much money is being spent on doctor in conferences? Pharma companies, associations may soon have make those declarations

The pharma companies and medical associations might need to disclose in the future the money they spend per doctor in conferences, a recent media report by The Print has stated.

Recommendations in this regard were made by a high-level government panel set up to review the Uniform Code of Pharmaceutical Marketing Practices (UCPMP).

Apart from this, the panel has also suggested that the doctors cannot be given brand reminders, in case the value exceeds Rs 1,000 per item. Brand reminders refer to products that are offered for free to doctors by marketing representatives of pharma companies with the names of popular medicinal brands.

For more details, check out the link given below:

How Much Money Is Being Spent On Doctor In Conferences? Pharma Companies, Associations May Soon Have Make Those Declarations

Powered by WPeMatico

Add on Metformin to insulin in pregnant women with diabetes fails to reduce neonatal complications: JAMA

USA: Metformin plus insulin treatment for preexisting type 2 or gestational diabetes diagnosed early in pregnancy failed to reduce a composite neonatal adverse outcome, a recent study published in the Journal of the American Medical Association (JAMA) has revealed.

In a randomized clinical trial of 794 pregnant women (18-45 years), metformin added to insulin for treating preexisting diabetes or diabetes identified in early pregnancy did not reduce a composite adverse neonatal outcome (71% vs 74%) compared with placebo but resulted in fewer large-for-gestational-age infants.

For pregnant women with preexisting type 2 diabetes (T2D) or diabetes diagnosed early in pregnancy, insulin is recommended. Previous studies have shown that metformin addition to insulin improves neonatal outcomes. Kim A. Boggess, University of North Carolina at Chapel Hill School of Medicine, and colleagues aimed to estimate the effect of metformin added to insulin for preexisting type 2 or diabetes diagnosed early in pregnancy on a composite adverse neonatal outcome.

The randomized clinical trial conducted in 17 US centres enrolled pregnant adults (18 to 45 years) with pre-existing T2D or diabetes diagnosed before 23 weeks gestation between 2019 and 2021. Each participant was given insulin treatment and was assigned to either metformin 1000 mg (n=397) or placebo (n=397) orally twice per day from enrollment (11 weeks -<23 weeks) through delivery.

The primary outcome of the study was a composite of neonatal complications including preterm birth, perinatal death, hyperbilirubinemia, and large or small for gestational age requiring phototherapy.

Prespecified secondary outcomes were neonatal fat mass at birth and maternal hypoglycemia, and prespecified subgroup analyses by maternal BMI less than 30 vs 30 or greater and those with preexisting vs diabetes early in pregnancy.

The study revealed the following findings:

  • The composite adverse neonatal outcome occurred in 71% of the metformin group and 74% of the placebo group (adjusted odds ratio, 0.86).
  • The most commonly occurring events in the primary outcome in both groups were neonatal hypoglycemia, preterm birth, and delivery of a large-for-gestational-age infant.
  • The study was halted at 75% accrual for futility in detecting a significant difference in the primary outcome.
  • Prespecified secondary outcomes and subgroup analyses were similar between groups.
  • Of individual components of the composite adverse neonatal outcome, metformin-exposed neonates had lower odds of being large for gestational age (adjusted odds ratio, 0.63) when compared with the placebo group.

“Using insulin plus metformin to treat preexisting type 2 or gestational diabetes diagnosed early in pregnancy failed to reduce a composite neonatal adverse outcome,” the researchers wrote.

“The effect of reduction in odds of a large-for-gestational-age infant seen after metformin addition to insulin warrants further investigation.”

Reference:

Boggess KA, Valint A, Refuerzo JS, et al. Metformin Plus Insulin for Preexisting Diabetes or Gestational Diabetes in Early Pregnancy: The MOMPOD Randomized Clinical Trial. JAMA. 2023;330(22):2182–2190. doi:10.1001/jama.2023.22949

Powered by WPeMatico

NBE tells 326 Diploma, DNB, FNB doctors to either complete registration process or get PG, SS admission cancelled

Noting that around 326 doctors have not completed their registration formalities with the National Board of Examinations (NBE) for the year 2021 and 2022, the NBE has now given them a last warning to either complete the process by December 15th or get their admissions cancelled.

Through a recent notice, National Board of Examinations (NBE) has informed regarding the Cancellation of candidature of 2021 and 2022 Admission Session trainees to pursue NBEMS courses.

For more details, check out the link given below:

Either Complete Registration Process Or Get Your PG, SS Admission Cancelled: NBE Tells 326 Diploma, DNB, FNB Doctors

Powered by WPeMatico

Marstacimab Therapy for Hemophilia Shows Long-term Efficacy and Safety

A recent study demonstrated significant efficacy and safety of monoclonal antibody Marstacimab in the long-term management of severe hemophilia A (HA) or hemophilia B (HB) without inhibitors. This outcomes from the pivotal Phase 3 BASIS study could revolutionize the approach to treat bleeding disorders. The findings were published in American Society of Hematology.

Marstacimab enhances hemostasis through the extrinsic pathway of blood coagulation and already has shown promise in previous studies. Early Phase 1/2 trials indicated its effectiveness and safety in reducing bleeding episodes in adults with severe hemophilia A or B.

The study enrolled male participants aged 12 to 75 with severe HA or moderately severe to severe HB, with or without inhibitors. After a 6-month observational phase, participants were grouped into on-demand (OD) or routine prophylaxis (RP). The active treatment phase involved a subcutaneous loading dose of 300 mg followed by once-weekly 150 mg marstacimab.

The results involved 128 participants who showed impressive outcomes. The annualized bleeding rate (ABR) for treated bleeds significantly reduced for both OD and RP groups, with marstacimab demonstrating superiority over OD and RP therapy. Safety analyses revealed a favorable profile with less incidence of adverse events and no treatment-related serious adverse events recorded.

As a step forward, this study found that subcutaneous marstacimab given once-weekly is not only safe but also highly effective to reduce bleeding events for participants with severe HA or moderately severe to severe HB without inhibitors. The positive results persisted beyond the 12-month active treatment phase, providing hope for a paradigm shift in hemophilia management.

This highlights marstacimab as a potential game-changer for hemophilia treatment, offering hope to those suffering from challenging bleeding disorders. As the study participants move into the long-term extension (LTE) phase, the expectation is high for continued positive outcomes that could redefine hemophilia care.

Source:

Matino, D., Acharya, S., Palladino, A., Hwang, E., McDonald, R., Taylor, C. T., & Teeter, J. (2023). Efficacy and Safety of the Anti-Tissue Factor Pathway Inhibitor Marstacimab in Participants with Severe Hemophilia without Inhibitors: Results from the Phase 3 Basis Trial. In Blood (Vol. 142, Issue Supplement 1, pp. 285–285). American Society of Hematology. https://doi.org/10.1182/blood-2023-181263

Powered by WPeMatico

Media reports claiming failure in procuring contraceptives are Ill-informed, misleading

Responding to some media reports alleging that India’s family planning program is likely to get severely affected due to failure in procuring contraceptives by the country’s central procurement agency, the Central Medical Services Society (CMSS) under the government of India has issued a response stating that such reports are ill-informed and provides misleading information.

The Central Medical Services Society (CMSS), New Delhi, an autonomous body and a Central Procurement Agency under Union Ministry of Health and Family Welfare procures condoms for National Family Planning Programme and National AIDS Control Programme.

For more details, check out the link given below:

We Have Enough Contraceptives In India: Govt Debunks Myths On Condom Shortage

Powered by WPeMatico

Health Bulletin 14/December/2023

Here are the top health stories for the day:

Govt junks media reports claiming contraceptive shortage in India 

Responding to some media reports alleging that India’s family planning program is likely to get severely affected due to failure in procuring contraceptives by the country’s central procurement agency, the Central Medical Services Society (CMSS) under the government of India has issued a response stating that such reports are ill-informed and provides misleading information.

The Central Medical Services Society (CMSS), New Delhi, an autonomous body and a Central Procurement Agency under Union Ministry of Health and Family Welfare procures condoms for National Family Planning Programme and National AIDS Control Programme.

For more details, check out the link given below:

We Have Enough Contraceptives In India: Govt Debunks Myths On Condom Shortage


Either complete registration process or get your PG, SS admission cancelled: NBE tells 326 Diploma, DNB, FNB doctors

Noting that around 326 doctors have not completed their registration formalities with the National Board of Examinations (NBE) for the year 2021 and 2022, the NBE has now given them a last warning to either complete the process by December 15th or get their admissions cancelled.

Through a recent notice, National Board of Examinations (NBE) has informed regarding the Cancellation of candidature of 2021 and 2022 Admission Session trainees to pursue NBEMS courses.

For more details, check out the link given below:

Either Complete Registration Process Or Get Your PG, SS Admission Cancelled: NBE Tells 326 Diploma, DNB, FNB Doctors

How much money is being spent on doctor in conferences? Pharma companies, associations may soon have make those declarations

The pharma companies and medical associations might need to disclose in the future the money they spend per doctor in conferences, a recent media report by The Print has stated.

Recommendations in this regard were made by a high-level government panel set up to review the Uniform Code of Pharmaceutical Marketing Practices (UCPMP).

Apart from this, the panel has also suggested that the doctors cannot be given brand reminders, in case the value exceeds Rs 1,000 per item. Brand reminders refer to products that are offered for free to doctors by marketing representatives of pharma companies with the names of popular medicinal brands.

For more details, check out the link given below:

How Much Money Is Being Spent On Doctor In Conferences? Pharma Companies, Associations May Soon Have Make Those Declarations

Powered by WPeMatico

Study reveals Hashimoto’s thyroiditis does not increase melanoma risk

USA: A retrospective matched cohort study found that Hashimoto’s thyroiditis does not raise the risk of melanoma and nonmelanoma skin cancer (NMSC).

The findings published in the Archives of Dermatological Research suggest that the local proinflammatory environment present in Hashimoto does not significantly contribute to the risk of melanoma.

Hashimoto’s is an autoimmune disorder. Normally, the autoimmune system protects the body by attacking viruses and bacteria. But with the disease, the immune system attacks the thyroid gland by mistake. The thyroid fails to produce sufficient thyroid hormone, resulting in body dysfunction.

An inflammatory microenvironment has been suggested to raise the risk of malignant melanoma, indicating that melanoma may be related to an inflammatory state. Hashimoto’s thyroiditis is one of the most common autoimmune diseases, yet no study has been conducted on its relationship with melanoma.

B. G. Gorman, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN, USA, and colleagues aimed to determine whether Hashimoto’s increases the risk of developing melanoma in a retrospective study.

For this purpose, the researchers identified a retrospective, validated cohort of patients with Hashimoto’s diagnosis between 2005 and 2020 using the Olmsted County database. Patients were sex and age-matched to controls without a Hashimoto diagnosis. The study’s primary outcomes were the melanoma development and the time to first diagnosis of melanoma.

The study led to the following findings:

  • 4805 patients were included in the study, with 36% having a diagnosis of Hashimoto’s.
  • Hashimoto’s patients had no significant difference in risk of melanoma (relative risk 0.96) or nonmelanoma skin cancer (relative risk 0.95) compared with matched controls, suggesting that, despite its potential pro-inflammatory effects, Hashimoto’s thyroiditis does not appear to contribute to the risk of melanoma significantly.

“The study findings suggest that Hashimoto’s thyroiditis does not increase the risk of melanoma and NMSC,” the researchers wrote.

“There may be a need for larger studies to characterize the relationship between these diseases further,” they concluded.

Reference:

Gorman, B.G., Campbell, E., Mullen, B.L. et al. Association between Hashimoto’s thyroiditis and melanoma: a retrospective matched cohort study. Arch Dermatol Res 315, 2721–2724 (2023). https://doi.org/10.1007/s00403-023-02669-4

Powered by WPeMatico

71 seats available for INI SS January 2024 at JIPMER: Know eligibility criteria, seat matrix, fee, all admission details here

Puducherry: Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) has released the information brochure regarding the admission procedure for the INI SS ( DM/MCh) course – January 2024 session concerning the first counselling for students.

As per the notice, the allotted candidates need to report by 18th December 2023 from 9:30 AM to 11:30 AM at the Academic Section, Third floor, JIPMER Academic Centre (JAC). Except 17th December 2023, i.e., Sunday.

For candidates who choose Option 1 in the first counselling (accepted the seat): The admission process will span over a minimum of two working days.

Tasks to be completed before reaching the admission venue –

Complete the Health-Care Professional ID Registration –

Steps for registration in NDHM / ABDM (Health-Care Professional ID Registration –

1. Click the below mentioned link to Register ‘Professional Healthcare ID’. The link is mentioned in the notice below.

2. Click on ‘Create Your Healthcare Professional ID now’. Step 3: Click on ‘I am Healthcare Professional’.

3. Click on ‘Generate via Aadhaar’. Step 5: Enter your Aadhaar Number.

4. Click on ‘I agree’ and click on ‘Submit’.

5. The candidates will get a 6-digit ‘OTP’ to their Aadhaar Registered Mobile Number. Step 8: Enter the OTP and Click ‘Login’.

6. After logging in, enter your Mobile Number.

7. The candidates will get again 6 digit ‘OTP’ on their mobile number. Step 11: Enter OTP and click on Login.

8. After logging in, create your ‘User Name’ & ‘Password’ (Password must be 8 characters, Upper case, lower case, Alphanumeric and special character).

9. Select ‘I am Healthcare Professional’. Step 14: Select ‘Modern Medicine’.

10. Enter your email address and click on ‘submit’.

11. After Submitting, the candidates will get OTP on their email for verification; after verification, their Registration will be completed, and you will receive a 14-digit Professional Healthcare ID number, take a printout of this page and submit the same at the time of document verification.

Fill out the E-form by clicking the link mentioned in the notice below & take a printout after final submission.

Forms to be printed and brought to the venue –

1. E-Form as mentioned above

2. ID card form – all the fields should be filled and in block letters (Annexure 1)

3. Joining letter and joining report formats (Annexures 2 & 3)

4. Hostel application form (if applicable) (Annexure 4)

5. Photocopy of Aadhaar card and PAN card (original should be brought during admission for verification)

On the day of reporting –

The following steps should be completed in the given order –

Day 1 –

Please provide an Institute Allocation Slip (printed after choosing Option-I or Option-II in the AIIMS portal) and print the e-form given above to the team and take a seat.

The candidates will be called at certificate verification desks inside the hall. Please produce all required documents in original, 1 set of photocopies of the original certificates, and 4 passport-size photographs.

After successful certificate verification, you will be given a form for Medical Examination by the team. The place of Medical Examination will be informed on the day of reporting. The duly signed Medical Examination report should be submitted back to the admission team. MEDICAL EXAMINATION WILL NOT BE CONDUCTED ON SATURDAYS.

Day 2 –

Submission of agreement form: A soft copy of the Resident Agreement form will be provided to the candidates; they have to go out and get it printed on Stamp Paper, and they have to fill it out as per the instructions given by JIPMER authorities at the time of document verification and submit to the authorities after filling it.

Complete the fee payment procedure through the SBI Collect payment portal for JIPMER at the link mentioned in the notice below.

Search for “JIPMER” in the search bar (Search by Institution / Organisation Name), and Select JIPMER PONDICHERRY from the two search results. Clicking on “JIPMER PONDICHERRY will redirect you to the next web page.

Choose the “Academic fee – MCh DM MD MS PDF PDCC” option in the dropdown menu given against the Payment Category. Refer to the prospectus for the correct split-up of fees (as given on page number 7 of Prospectus Part B for JIPMER).

The fee, once paid, cannot be refunded under any circumstances. Submit the hard copy of the fee payment receipt to the admission team.

The following will be issued to the candidates after completion of the above steps –

1. Bonafide certificate (certifying that the original documents are retained by the institute)

2. Provisional Admission order

Submit –

1. Hostel application form (if needed).

2. ID card form. The form has a field for the residential address (in Puducherry). The candidates may fill the field either after allotment of a hostel room or after renting accommodation outside the campus and submit this form.

The filled-in joining letter and joining report forms should be submitted to the respective department office on July 1, 2022. The joining report will be sent to the Academic Section by the department later through the proper channel.

If any candidate who has been allotted a seat in JIPMER chooses OPTION-1 and reports for admission in JIPMER as per the schedule given in the INI-SS result notification, his / her certificates will be retained after verification of the same. If any such candidate decides to leave the seat after submission of certificates to JIPMER authorities but before completion of joining / admission formalities and getting admission order / joining the department, he / she will be liable to pay the penalty to JIPMER which is Rs. 3 Lakhs. Additionally, the fee paid by him/her for admission will not be refunded.

Subject to the result of facial and iris verification.

For candidates who choose Option 2 –

Candidates should report as per the schedule mentioned above and submit either of the certificates mentioned in the prospectus.

Or

Security deposit as mentioned in the INI-SS result notification.

A Bonafide certificate will be issued for the retained certificates.

Seats vacant –

A total of 71 seats are vacant. DM Courses have 39 seats, and MCH courses have 32 seats vacant. The detailed course-wise seat matrix is enclosed in the notice below. The number and distribution of seats are subject to variation based on any periodic directives from the Competent Authority.

Eligibility criteria –

1. Candidates should be Indian Nationals.

2. Candidates should have passed MD/MS/DNB degrees from any Institute/University recognized by the National Medical Commission (NMC).

3. The degree mentioned above must be registered with the National Medical Commission/State Medical Council.

4. Candidates should have completed the qualifying postgraduate course on or before January 31, 2024.

DM courses

Eligibility

Critical Care

MD/DNB Anaesthesiology/General Medicine/Pulmonary Medicine

Cardiac Anaesthesia

MD/DNB Anaesthesiology

Neuro Anaesthesia

Cardiology

MD/DNB General Medicine/Paediatrics/Pulmonary Medicine

Clinical Pharmacology

MD/DNB General Medicine/Pharmacology/Paediatrics

Clinical Immunology & Rheumatology

MD/DNB Degree in General Medicine/Paediatrics

Endocrinology

Nephrology

Neurology

Medical Oncology

MD/DNB Medicine/Paediatrics/Radiotherapy

Neonatology

MD/DNB Paediatrics

Paediatric Critical care

Medical Gastroenterology

MD/DNB General Medicine/Paediatrics

Neuroimaging and Interventions

MD/DNB Radiodiagnosis

MCh courses

Eligibility

Urology

MS/DNB General Surgery

CTVS

Neurosurgery

Surgical Gastroenterology

Plastic Surgery

Paediatric Surgery

Surgical Oncology

MS/DNB General Surgery/Obstetrics & Gynaecology/ Otorhinolaryngology
(ENT)/Orthopaedic Surgery

Gynecological Oncology

MD/MS/DNB Obstetrics & Gynaecology

Sponsored category (Government – State/Central Services) –

A candidate applying under a sponsored category is required
to fulfill the following conditions duly certified by his/her
sponsoring/deputing authority/employer. The candidate is required to submit the
scanned copy of the sponsorship certificate in the format as given in the
Prospectus Part- A.

In case the applicant is not able to upload the sponsorship
certificate at the time of submission of the online application, he/she is
permitted to upload a scanned copy of the sponsorship certificate (.jpg/pdf) using
his/her login credentials as mentioned in the Prospectus Part- A in the
database. Non-receipt of scanned copy in the database of such candidate will
lead to automatic rejection of his/her application, and a hall ticket will not be
generated/issued. The sponsored certificate should contain the following
declaration by the sponsoring authority.

1. That the candidate concerned is a permanent or regular employee of the deputing/ sponsoring authority and should have been working for at least the last three years (as of 31st December 2023 for the January 2024 session)

2. After getting training at JIPMER, Puducherry, the candidate will be suitably employed by the deputing/sponsoring authority to work for at least five years in the specialty in which training is received by the candidate at JIPMER.

3. No financial implications, in the form of emoluments/stipend, etc., will devolve upon JIPMER, Puducherry, during the entire period of his/her course and such payment shall be the responsibility of the sponsoring authority.

Deputation/Sponsorship of candidates holding tenure appointments (like house job, Junior or Senior Residency, ad-hoc or contract, or honorary appointment against a leave vacancy) shall NOT be accepted. Deputation/Sponsorship of any candidate by private hospitals, institutes, or nursing homes is not accepted. The sponsoring Institute should not nominate more than one candidate for each of the specialties specified in the distribution of seats in the discipline.

Sponsorship/Deputation of candidates will be accepted only from the following –

1. Central or State Government Departments/Institutions

2. Autonomous Bodies of the Central or State Governments

3. Public sector colleges affiliated to Universities and recognized by the National Medical Commission. For candidates deputed/ sponsored by the Medical College affiliated with Universities and recognized by the National Medical Commission, a deputation/sponsorship certificate signed by the Principal of the Medical College concerned ONLY shall be accepted.

Selection of Sponsored Candidates –

Sponsored/Deputed candidates are also required to appear in the common entrance examination. Separate merit lists will be drawn for each of the specified disciplines for sponsored candidates. If selected for admission to any course of JIPMER, these candidates are required to make their own arrangements for stay during the period of their course. The sponsored candidates selected for admission will be granted only one-month time to produce Sponsorship/Relieving/Study leave/NOC certificates from the date of announcement of the results of the respective counselling. No further extension will be allowed under any circumstances. Vacant seats under the sponsored category will not be transferred to the general category.

Method of selection and admission process –

The selection of candidates is based on the INI-SS entrance examination without an interview component. Allotment of the institution is based on merit scores and the choice exercised by the candidates in the online INI-SS counseling process conducted by AIIMS, New Delhi.

Candidates who have opted for a seat at JIPMER and were selected through counseling shall undergo a medical examination and biometric (iris/signature) verification. After due verification of the documents, clearance of biometric parameters, and medical fitness certified by a competent authority nominated by the Institute, an admission letter will be issued. The Original Certificates will be retained in the Academic Section and returned only after the candidate completes the course or if relieved before completion of the course for any reason. The academic session will commence on January 01, 2024.

It is mandatory for all candidates to be physically present in person for admission. No request for an authorized representative on behalf of the candidate will be entertained. If a candidate fails to come for admission in person, he/she will be marked as absent, and the admission will be canceled. Admissions close on February 29, 2024.

Verification of original certificates –

FULL NAME entered by the candidate must match with both his/her Govt. Photo ID Card (Aadhar Card / PAN card / Identity Card / Driver’s License etc.) and MD/MS/DNB Degree Certificate. (Spelling and order must be same – if it is not the same, the candidate is advised to get it changed in the above-mentioned document/documents.

The candidate should submit the following certificates in original along with one set of self-attested copies at the time of admission – 

1. Hall Ticket for INISS entrance examination.

2. Rank Letter and Seat Allotment letter.

3. Proof of Date of Birth (Birth Certificate or X Std. Certificate).

4. MBBS Degree Certificate

5. MD/MS/DNB Degree Certificate/Provisional Pass Certificate.

6. MD/MS/DNB Marksheet

7. Character and Conduct Certificate from the Head of the Institute last studied.

8. Residence Certificate issued by Revenue Authority, not below the rank of Tahsildar

9. Transfer Certificate from the Head of the Institution last studied / Migration Certificate from the University last studied. *

10. Permanent Medical Registration Certificate from the National Medical Commission (or State Medical Council)

11. Registration of Additional Medical qualifications with the National Medical Commission

12. The service candidate should produce an NOC/Relieving Order and a certificate granting study leave with or without pay, as the case may be (If applicable)

13. Four Passport size color photographs identical to the photograph uploaded in the application.

A maximum one-week time may be granted from the date of issue of the provisional admission order to submit this certificate; failure to submit it will lead to cancellation of admission.

If the certificates are in a language other than English, an English translation attested by a Gazetted Officer should be produced.

A candidate will be eligible for admission if his /her Biometric fingerprint or iris scan, photo, and necessary certificates are found in order. If there is any mismatch, the seat allotment will be canceled, apart from proceeding with legal action deemed fit by the Institution, and no further correspondence will be entertained in this regard. If a candidate is already pursuing any other courses at any Institution, he/she shall submit the necessary no-objection certificate from the concerned Institution authority at the time of admission. It will be applicable to JIPMER candidates also.

Candidates must join the course after the medical examination on or before the stipulated date given in the letter of admission. The admission of candidates who fail to pay the specified fee or fail to report for duty to the concerned Head of the Department will be treated as canceled. No further correspondence will be made in this regard. Extension of joining time shall not be granted under any circumstances. The Senior Resident should send his/her joining Report to the Director through the concerned Head of the Department.

If a Senior Resident remains continuously absent or unauthorized for more than 30 days after joining, the admission will be canceled, and the necessary penalty will be levied. Admission to the course will be provisional, subject to the recognition of the qualifying examination of individual candidates by JIPMER. Admission fees paid will not be refunded.

Fee structure – 

Sl.No.

Description

Fee in INR

1

Admission Fee

3,000

2

Tuition Fee (per annum)

2,200

3

Learning Resource Fee (per annum)

15,000

4

Corpus Fund on Academic Fee (per annum)

110

5

Student information details (per annum)

1,500

6

Identity Card Charges

150

7

Caution deposit (refundable *)

3,000

TOTAL

24,960

Caution deposit will be refunded only on successful
completion of the course. Fees, once paid, will NOT be refunded under any
circumstances.

Hostel charges –

Sl. No.

Description

Fee in INR

1.

Hostel Caution Deposit (refundable)

5,000

2.

Hostel Mess Deposit (refundable)

3,000

3.

Student Recreation/Amenities (per annum)

1,000

4.

Establishment Charges (per annum)

6,000

5.

Room Rent (per annum) including Electricity Charges for a single
room = Rs.9,000/-

9,000

TOTAL

24,000

To view the notices, click on the links below –

https://medicaldialogues.in/pdf_upload/iniss-prospectus-jan-2024-part-b-jipmer-227768.pdf

Powered by WPeMatico

Noida: Yatharth Super Specialty Hospital, Apex Eye and IVF Center slapped Rs 5 lakh fine each for illegal billboard ads

Noida: The Greater Noida Industrial Development Authority on Wednesday said it has slapped penalties worth Rs 5 lakh each on six entities, including two schools, a hospital, and a banquet hall, for illegally installing billboards for advertisements.

In total, penalties worth Rs 30 lakh were imposed on the offenders by the Urban Services Department which inspected different locations of the city on instructions of GNIDA’s Chief Executive Officer N G Ravi Kumar, it said in a statement.

Also Read:Nagpur Hospital fined Rs 50000 over biomedical waste violations

“The GNIDA’s team imposed fines on these illegal unipoles and directed the entities concerned to remove them immediately. The institutions that have been fined for illegal unipoles include Shri Ram Global School, Yatharth Super Specialty Hospital, Saawariya Banquet Hall, Delhi World Public School, Apex Eye and IVF Center, and Sumiram Sai Realtors,” the GNIDA said in the statement.

“A penalty of Rs 5 lakh each — Rs 30 lakh — has been imposed on these six institutions by the Urban Services Department of the authority. A warning has also been given to issue a recovery certificate if this amount of fine is not deposited in the authority’s account within a week,” it added.

Along with this, the illegal unipoles which do not have advertisements but disrupt traffic movement will also be removed, the local authority said.

GNIDA’s Officer on Special Duty Indu Prakash Singh said similar action against those setting up statutory poles illegally will continue in the future, according to the statement.

A unipole sign is a frame structure mounted atop a single column used in outdoor advertising.

Powered by WPeMatico

No shortage of TB drugs in India: Govt

New Delhi: The Ministry of Health & Family Welfare has informed that there is no shortage of anti-tuberculosis drugs in the country. There has been regular supply of Anti-TB drugs to all the State/UTs from the central level under the National TB Elimination Programme (NTEP) throughout the year and regular assessments are conducted to evaluate the stock positions at various levels, from central warehouses to peripheral health institutes.

Further, State/UTs have been provisioned with resources for local procurement for limited quantities as and when required to meet the emergent requirements.

The details of stock positions of anti-tuberculosis drugs placed are as under:

Stock of Anti TB Drugs as on 06-12-2023

Drug Name

Total Stock available

Stocks will last

(approx. months)

Tab. 2FDC (P) (H50 & R75)

18078984

More than 6 months

Tab.3FDC CP (A) (H75,R150 & E275)

159287016

For 4 months

Tab 3FDC(P) (H50, R75, Z150)

17889844

More than 6 months

Tab. 4FDC(A) (H75, R150, Z400 & E275)

94250072

For 4 months

Tab. Bedaquiline (BDQ)-L

9835849

More than 6 months

Cap. Clofazimine 100mg

7901607

More than 6 months

Cap. Clofazimine 50mg

129405

More than 6 months

Cap. Cycloserine 250mg

12591104

More than 6 months

Tab. Delamanid 50mg

3688946

More than 6 months

Tab. Ethambutol 100mg

40895959

More than 6 months

Tab. Ethambutol 800mg

2759910

For 3 months

Tab. Ethionamide 250mg

15096309

More than 6 months

Tab. Moxifloxacin 400mg

25720793

More than 6 months

Tab. Isoniazid 300mg

43951761

More than 6 months

Tab. Levofloxacin 250mg

10770158

More than 6 months

Tab. Levofloxacin 500mg

9862422

More than 6 months

Tab Linezolid 600mg

4190760

More than 6 months

Tab. Pyrazinamide 500mg

6262558

More than 6 months

Tab. Pyrazinamide 750mg

5862684

More than 6 months

Tab. Pyridoxine 100mg

20060750

More than 6 months

Read also: Vague and ill-informed: Centre dismisses claims on shortage of anti-TB drugs in India

Powered by WPeMatico